



Cost-Effectiveness Analysis Report

Quick Analysis

Report Date:	2026-01-19 17:47:02	Generated By:	anonymous@ecomodel.com
Organization:	Demo	Model Type:	Markov 3-State

Executive Summary

ICER

€1,412,285

per QALY gained

ΔQALYS

1.287

Quality-adjusted life years

ΔCOSTS

€1,817,470

Incremental costs

CONCLUSION

Not Cost-Effective

at €30,000/QALY

Clinical and Economic Interpretation

The new treatment (Drug A) is **not cost-effective** compared to the standard treatment (Drug B) at the willingness-to-pay threshold of €30,000 per QALY gained. The incremental cost-effectiveness ratio (ICER) of €1,412,285/QALY exceeds the established threshold. While the treatment provides an additional 1.287 QALYs, the incremental cost of €1,817,470 is not justified at the current WTP threshold.

Model Parameters

Cost Parameters

Drug A Cost (€/cycle):	€3,500	Drug B Cost (€/cycle):	€2,800
Healthcare Cost - Stable (€):	€200	Healthcare Cost - Progression (€):	€4,500

Clinical Parameters

Progression Risk - Drug A:	10.0%	Progression Risk - Drug B:	25.0%
Utility - Stable:	0.85	Utility - Progression:	0.50

Model Settings

Time Horizon:	10 years	Discount Rate:	3.0%
WTP Threshold:	€30,000/QALY	Cycle Length:	1 year

Detailed Results

Comparative Effectiveness and Costs

Metric	Drug A (New)	Drug B (Standard)	Difference (Δ)
Total Costs (€)	€32,889,110	€31,071,640	€1,817,470
Total QALYs	4.933	3.646	1.287
Life Years	7.62	6.43	1.19
ICER (€/QALY)		€1,412,285	

Generated by EcoModel Hub - Professional HEOR Platform

This report was automatically generated on 2026-01-19 17:47:02 by anonymous@ecomodel.com

Confidential - For internal use only

Disclaimer: This analysis is based on the parameters and assumptions provided. Results should be interpreted in the context of clinical evidence and local healthcare settings. This report does not constitute medical advice or reimbursement recommendations.